Stocktoria
UroGen Pharma Ltd. URGN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-05-04
UroGen Pharma Ltd. statistics & valuation
Market cap$1.6B
P / S14.2×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 88.7% | 90.2% | 88.7% | 88.1% | 89.3% |
| Operating margin | -113.7% | -107.1% | -79.2% | -122.8% | -192.1% |
| Net margin | -139.8% | -140.4% | -123.6% | -170.6% | -230.7% |
| FCF margin | -148.2% | -107.4% | -92.6% | -136.4% | -178.3% |
| Return on assets | -76.6% | -44.4% | -57.3% | -80.9% | -92.5% |
| Return on equity | 145.5% | 1441.3% | 156.8% | 122.9% | -1317.2% |
| Debt / equity | -1.19× | -13.83× | -1.51× | -1.09× | 0.00× |
| Current ratio | 4.01 | 6.01 | 5.42 | 5.39 | 5.11 |
| Revenue growth | 21.4% | 9.3% | 28.5% | 34.0% | 307.2% |
Source: SEC EDGAR filings · CIK 0001668243 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.